ATAI Life Sciences Overview

  • Founded
  • 2018

Founded
  • Status
  • Public

  • Employees
  • 87

Employees
  • Stock Symbol
  • ATAI

Stock Symbol
  • Investments
  • 16

  • Share Price
  • $1.88

  • (As of Tuesday Closing)

ATAI Life Sciences General Information

Description

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.

Contact Information

Website
www.atai.life
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • C/o Mindspace
  • Krausenstraße 9-10
  • 10117 Berlin
  • Germany
+49 089 00000000

ATAI Life Sciences Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ATAI Life Sciences Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.88 $1.93 $1.45 - $6.32 $320M 166M 1.52M -$1.31

ATAI Life Sciences Financials Summary

In Thousands,
USD
TTM 30-Sep-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 245,627 803,177
Revenue 425 20,376 0 0
EBITDA (144,782) (136,759) (101,860) (17,491)
Net Income (196,251) (167,808) (169,843) (14,138)
Total Assets 342,597 414,166 111,548 62,116
Total Debt 15,001 743 2,177 157
Public Fundamental Data provided by Morningstar, Inc. disclaimer

ATAI Life Sciences Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore ATAI Life Sciences‘s full profile, request access.

Request a free trial

ATAI Life Sciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health d
Drug Discovery
Berlin, Germany
87 As of 2021
00000
0.000 0000-00-00
00000000 00000

000000

irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nu
0000 000000000
Boston, MA
000 As of 0000
00000
0.000 0000-00-00
00000000 00000

0000 0

u fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in
0000 000000000
Cambridge, MA
000 As of 0000
00.000
000000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ATAI Life Sciences Competitors (3)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Karuna Therapeutics Formerly VC-backed Boston, MA 000 00000 00000000 00000
0000 000000000000 Formerly VC-backed Cambridge, MA 000 00.000 000000000 00.000
000000 00000000000 Corporation New York, NY 000 000.00 00000000 000.00
You’re viewing 3 of 3 competitors. Get the full list »

ATAI Life Sciences Patents

ATAI Life Sciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230024991-A1 Prodrugs of acyl carnitines Pending 23-Jun-2021 0000000000
US-20220388956-A1 New n,n-dimethyltryptamine salts and crystalline salt forms Pending 25-May-2021 0000000000
US-20220339139-A1 Novel n,n-dimethyltryptamine compositions and methods Pending 26-Apr-2021 00000000000 0
FR-1486515-A Sealed contact valve for fluid passage Inactive 27-May-1966 F16K31/365

ATAI Life Sciences Executive Team (14)

Name Title Board Seat Contact Info
Florian Brand Chief Executive Officer & Founder
Stephen Bardin Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Srinivas Rao Ph.D Chief Scientific Officer & Founder
Srinivas Rao Ph.D Co-Founder & Chief Scientific Officer
Aaron Weaver Senior General Counsel and Lead Investor Relations
You’re viewing 5 of 14 executive team members. Get the full list »

ATAI Life Sciences Board Members (8)

Name Representing Role Since
Andrea Smiley ATAI Life Sciences Board Member 000 0000
Christian Angermayer Self Chairman & Founder 000 0000
Gregory Weaver Self Chief Financial Officer & Board Member 000 0000
Jason Camm Self Board Member 000 0000
Michael Auerbach Self Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

ATAI Life Sciences Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ATAI Life Sciences Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore ATAI Life Sciences‘s full profile, request access.

Request a free trial

ATAI Life Sciences Investments & Acquisitions (16)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000000 09-Dec-2021 00000 0000 Drug Discovery 0000000 0
000000000 000 14-May-2021 0000 0000 Drug Delivery 0000000 0
000000 07-Apr-2021 0000000000 Therapeutic Devices 000000000
000000000 000 06-Nov-2020 0000000000 Drug Discovery 00000000
Kures 09-Jul-2020 Merger/Acquisition Drug Discovery 0000000 0
You’re viewing 5 of 16 investments and acquisitions. Get the full list »

ATAI Life Sciences Subsidiaries (3)

Company Name Industry Location Founded
Recognify Life Sciences Drug Discovery Berlin, Germany 2018
00000 Drug Discovery Dobbs Ferry, NY 0000
000000 Therapeutic Devices New York, NY
To view ATAI Life Sciences’s complete subsidiaries history, request access »

ATAI Life Sciences ESG

Risk Overview

Risk Rating

Updated November, 23, 2022

32.83 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.00

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 15,638

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 1,008

Rank

00.00

Percentile

Pharmaceuticals

Subindustry

00 of 473

Rank

00.00

Percentile

To view ATAI Life Sciences’s complete esg history, request access »

ATAI Life Sciences Exits (3)

Company Name Exit Date Exit Type Exit Size Status Buyers
0000000 00000000 17-Apr-2020 00000 00000 00 000.00 Completed
  • 19 buyers
0000000 00000000 20-Sep-2018 00000 00000 00 000.00 Completed
  • 5 buyers
COMPASS Pathways Later Stage VC 000.00 Completed
To view ATAI Life Sciences’s complete exits history, request access »